Table 4 Phase II studies of gemcitabine/paclitaxel in patients with advanced or metastatic breast cancer
Author | Regimen | No. of Pts | ORR % (CR %) | Median TTP (mos) | Comments |
|---|---|---|---|---|---|
Vici et al26 | G 1500 mg/m2 d1, 15 + T150 mg/m2 d1, 15 q4wks | 20 | 45% (10%) | 8 | Heavily pretreated pts; supported with G-CSF |
Colomer et al27 | G 2500 mg/m2 d1 + T150 mg/m2 d1 q2wks | 43 | 68% (21%) | 9 | Previously treated pts; hematologic toxicity |
Delfino et al28 | G 1200 mg/m2 d1, 8 + T 175 mg/m2 d1 q3wks | 45 | 67% (22%) | 11 | Chemonaïve pts; mild hematologic toxicity; manageable toxicity |
Sanchez-Rovira et al29 | G 2500 mg/m2 d1, 15 + T 135 mg/m2 d1, 15 q4wks | 44 | 45% (7%) | 7 | Previously treated pts; hematologic and neurologic toxicities |
Murad et al30 | G 1000 mg/m2 d1, 8 + T 175 mg/m2 d1 q3wks | 29 | 55% (17%) | 8 | Heavily pretreated pts; 28-day reduced to a 21-day schedule due to hematologic toxicity |
Genot et al (current study) | G 1200 mg/m2 d1, 8 T 175 mg/m2 d1 q3wks | 40 | 40% (5.7%) | 7.2 | No prior treatment for metastatic disease, neutropenia prominent, other toxicities mild |